Does the media refer more to ALLO or CRSP?

In the previous week, CRISPR Therapeutics had 12 more articles in the media than Allogene Therapeutics. MarketBeat recorded 19 mentions for CRISPR Therapeutics and 7 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.56 beat CRISPR Therapeutics' score of 0.22 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media prefer CRSP or AXSM?

In the previous week, Axsome Therapeutics had 1 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 20 mentions for Axsome Therapeutics and 19 mentions for CRISPR Therapeutics. Axsome Therapeutics' average media sentiment score of 0.24 beat CRISPR Therapeutics' score of 0.22 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Axsome Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media favor CRSP or BEAM?

In the previous week, Beam Therapeutics had 5 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 24 mentions for Beam Therapeutics and 19 mentions for CRISPR Therapeutics. Beam Therapeutics' average media sentiment score of 0.76 beat CRISPR Therapeutics' score of 0.22 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Beam Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRSP or EDIT?

In the previous week, Editas Medicine had 2 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 21 mentions for Editas Medicine and 19 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.22 beat Editas Medicine's score of 0.18 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Editas Medicine 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer CRSP or KALA?

CRISPR Therapeutics currently has a consensus target price of $72.93, suggesting a potential upside of 72.65%. Given CRISPR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CRISPR Therapeutics is more favorable than KALA BIO. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRISPR Therapeutics 1 Sell rating(s) 6 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.65 KALA BIO 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer CRSP or KALA?

In the previous week, CRISPR Therapeutics had 14 more articles in the media than KALA BIO. MarketBeat recorded 19 mentions for CRISPR Therapeutics and 5 mentions for KALA BIO. CRISPR Therapeutics' average media sentiment score of 0.22 beat KALA BIO's score of -0.24 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral KALA BIO 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

CRISPR Therapeutics (CRSP) Competitors

$42.24 -0.38 (-0.89%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$42.33 +0.09 (+0.20%)

As of 11/13/2026 07:58 PM Eastern

Compare

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

Should you buy CRISPR Therapeutics stock or one of its competitors? CRISPR Therapeutics's main competitors and comparable companies include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), and KALA BIO (KALA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Allogene Therapeutics presently has a consensus price target of $8.30, suggesting a potential upside of 889.63%. CRISPR Therapeutics has a consensus price target of $72.93, suggesting a potential upside of 72.65%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.65

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Allogene Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	14,529.22	-$190.89M	-$0.63	N/A
CRISPR Therapeutics	$3.51M	1,167.32	-$581.60M	-$4.74	N/A

Allogene Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

In the previous week, CRISPR Therapeutics had 12 more articles in the media than Allogene Therapeutics. MarketBeat recorded 19 mentions for CRISPR Therapeutics and 7 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.56 beat CRISPR Therapeutics' score of 0.22 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,812.07%. CRISPR Therapeutics' return on equity of -25.59% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-49.84%	-37.25%
CRISPR Therapeutics	-1,812.07%	-25.59%	-17.89%

Summary

Allogene Therapeutics beats CRISPR Therapeutics on 10 of the 15 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Axsome Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Axsome Therapeutics has a net margin of -18.18% compared to CRISPR Therapeutics' net margin of -1,812.07%. CRISPR Therapeutics' return on equity of -25.59% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-1,812.07%	-25.59%	-17.89%
Axsome Therapeutics	-18.18%	-198.73%	-22.03%

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CRISPR Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

CRISPR Therapeutics presently has a consensus price target of $72.93, indicating a potential upside of 72.65%. Axsome Therapeutics has a consensus price target of $266.21, indicating a potential upside of 87.88%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.65
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86

Axsome Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,167.32	-$581.60M	-$4.74	N/A
Axsome Therapeutics	$638.50M	11.67	-$183.17M	-$3.06	N/A

In the previous week, Axsome Therapeutics had 1 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 20 mentions for Axsome Therapeutics and 19 mentions for CRISPR Therapeutics. Axsome Therapeutics' average media sentiment score of 0.24 beat CRISPR Therapeutics' score of 0.22 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Axsome Therapeutics	3 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Axsome Therapeutics beats CRISPR Therapeutics on 11 of the 17 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Beam Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Beam Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,167.32	-$581.60M	-$4.74	N/A
Beam Therapeutics	$139.74M	16.93	-$79.99M	-$1.04	N/A

In the previous week, Beam Therapeutics had 5 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 24 mentions for Beam Therapeutics and 19 mentions for CRISPR Therapeutics. Beam Therapeutics' average media sentiment score of 0.76 beat CRISPR Therapeutics' score of 0.22 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Beam Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CRISPR Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market.

Beam Therapeutics has a net margin of -73.04% compared to CRISPR Therapeutics' net margin of -1,812.07%. CRISPR Therapeutics' return on equity of -25.59% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-1,812.07%	-25.59%	-17.89%
Beam Therapeutics	-73.04%	-32.76%	-25.80%

CRISPR Therapeutics presently has a consensus target price of $72.93, suggesting a potential upside of 72.65%. Beam Therapeutics has a consensus target price of $47.64, suggesting a potential upside of 108.35%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.65
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

Beam Therapeutics beats CRISPR Therapeutics on 11 of the 17 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Editas Medicine?

CRISPR Therapeutics (NASDAQ:CRSP) and Editas Medicine (NASDAQ:EDIT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,167.32	-$581.60M	-$4.74	N/A
Editas Medicine	$49.83M	6.72	-$160.06M	-$0.62	N/A

In the previous week, Editas Medicine had 2 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 21 mentions for Editas Medicine and 19 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.22 beat Editas Medicine's score of 0.18 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Editas Medicine	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

CRISPR Therapeutics currently has a consensus price target of $72.93, indicating a potential upside of 72.65%. Editas Medicine has a consensus price target of $5.83, indicating a potential upside of 168.82%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.65
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Editas Medicine has a net margin of -144.95% compared to CRISPR Therapeutics' net margin of -1,812.07%. CRISPR Therapeutics' return on equity of -25.59% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-1,812.07%	-25.59%	-17.89%
Editas Medicine	-144.95%	-130.43%	-36.45%

CRISPR Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Editas Medicine beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks.

How does CRISPR Therapeutics compare to KALA BIO?

CRISPR Therapeutics (NASDAQ:CRSP) and KALA BIO (NASDAQ:KALA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

In the previous week, CRISPR Therapeutics had 14 more articles in the media than KALA BIO. MarketBeat recorded 19 mentions for CRISPR Therapeutics and 5 mentions for KALA BIO. CRISPR Therapeutics' average media sentiment score of 0.22 beat KALA BIO's score of -0.24 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
KALA BIO	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

CRISPR Therapeutics currently has a consensus target price of $72.93, suggesting a potential upside of 72.65%. Given CRISPR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CRISPR Therapeutics is more favorable than KALA BIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.65
KALA BIO	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

KALA BIO has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,812.07%. CRISPR Therapeutics' return on equity of -25.59% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-1,812.07%	-25.59%	-17.89%
KALA BIO	N/A	-222.35%	-70.23%

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 2.2% of KALA BIO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

KALA BIO has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,167.32	-$581.60M	-$4.74	N/A
KALA BIO	N/A	N/A	-$26.98M	-$31.96	N/A

CRISPR Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.19, meaning that its share price is 319% less volatile than the broader market.

Summary

CRISPR Therapeutics beats KALA BIO on 13 of the 16 factors compared between the two stocks.

Get CRISPR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRSP vs. The Competition

Export

Metric	CRISPR Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.13B	$4.15B	$7.87B	$12.20B
Dividend Yield	N/A	3.62%	2.46%	4.53%
P/E Ratio	-8.91	24.48	34.56	30.66
Price / Sales	1,167.32	16.51	8.64	5.86
Price / Cash	N/A	26.37	21.93	22.49
Price / Book	2.49	4.00	4.35	3.76
Net Income	-$581.60M	-$22.86M	$3.52B	$390.95M
7 Day Performance	-15.64%	-2.82%	-1.52%	-0.34%
1 Month Performance	-18.01%	-5.39%	-3.54%	-5.79%
1 Year Performance	-19.59%	-1.71%	1.45%	-5.71%

CRISPR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRSP CRISPR Therapeutics	2.922 of 5 stars	$42.24 -0.9%	$72.93 +72.7%	N/A	$4.13B	$3.51M	N/A	393	Analyst Forecast
ALLO Allogene Therapeutics	3.1959 of 5 stars	$1.06 +1.9%	$8.30 +683.0%	N/A	$366.22M	$4.64M	N/A	152
AXSM Axsome Therapeutics	3.4187 of 5 stars	$133.96 +1.2%	$267.58 +99.7%	N/A	$7.05B	$638.50M	N/A	925	Analyst Forecast Analyst Revision Gap Down
BEAM Beam Therapeutics	2.7975 of 5 stars	$27.02 +2.3%	$47.36 +75.3%	N/A	$2.80B	$139.74M	N/A	540	Analyst Forecast Analyst Revision
EDIT Editas Medicine	2.3558 of 5 stars	$2.75 +7.0%	$5.83 +112.1%	N/A	$422.35M	$40.52M	N/A	87	News Coverage Earnings Report Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRSP) was last updated on 11/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CRISPR Therapeutics (CRSP) Competitors

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Summary

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Summary

How does CRISPR Therapeutics compare to Beam Therapeutics?

Summary

How does CRISPR Therapeutics compare to Editas Medicine?

Summary

How does CRISPR Therapeutics compare to KALA BIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP vs. The Competition

CRISPR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CRISPR Therapeutics (CRSP) Competitors

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Do analysts rate ALLO or CRSP?

Do insiders & institutionals hold more shares of ALLO or CRSP?

Which has preferable earnings and valuation, ALLO or CRSP?

Which has more risk & volatility, ALLO or CRSP?

Does the media refer more to ALLO or CRSP?

Is ALLO or CRSP more profitable?

Summary

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Is CRSP or AXSM more profitable?

Do insiders & institutionals have more ownership in CRSP or AXSM?

Which has more volatility and risk, CRSP or AXSM?

Do analysts rate CRSP or AXSM?

Which has higher valuation and earnings, CRSP or AXSM?

Does the media prefer CRSP or AXSM?

Summary

How does CRISPR Therapeutics compare to Beam Therapeutics?

Do institutionals and insiders have more ownership in CRSP or BEAM?

Which has stronger valuation and earnings, CRSP or BEAM?

Does the media favor CRSP or BEAM?

Which has more volatility and risk, CRSP or BEAM?

Is CRSP or BEAM more profitable?

Do analysts prefer CRSP or BEAM?

Summary

How does CRISPR Therapeutics compare to Editas Medicine?

Which has stronger valuation & earnings, CRSP or EDIT?

Does the media favor CRSP or EDIT?

Do analysts prefer CRSP or EDIT?

Is CRSP or EDIT more profitable?

Which has more volatility and risk, CRSP or EDIT?

Do insiders and institutionals believe in CRSP or EDIT?

Summary

How does CRISPR Therapeutics compare to KALA BIO?

Does the media prefer CRSP or KALA?

Do analysts prefer CRSP or KALA?

Is CRSP or KALA more profitable?

Do insiders & institutionals hold more shares of CRSP or KALA?

Which has stronger earnings and valuation, CRSP or KALA?

Which has more volatility & risk, CRSP or KALA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP vs. The Competition

CRISPR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools